Telaprevir gets EU go-ahead in hepatitis C
This article was originally published in Scrip
Executive Summary
Janssen's (J&J) novel hepatitis C protease inhibitor is catching up nicely with its chief rival, Merck & Co's boceprevir in Europe, having gained a positive opinion for approval from the EU's CHMP at its latest meeting.